Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2011
07/19/2011CA2578626C Modified-release formulations of a bupropion salt
07/19/2011CA2570758C Shaped implant material with antibiotic salts
07/19/2011CA2565944C Stabilized hyaluronan preparations and related methods
07/19/2011CA2526663C Indole derivatives with apoptosis-inducing effect
07/19/2011CA2509390C Method of treatment of prostate cancer and composition for treatment thereof
07/19/2011CA2507579C Pulverulent formulation for inhalation containing tiotropium
07/19/2011CA2494015C Antibiotic product, use and formulation thereof
07/19/2011CA2487722C New etonogestrel esters
07/19/2011CA2485702C Novel phosphonic acid based prodrugs of pmea and its analogues
07/19/2011CA2485677C Methods of treating allergic reactions
07/19/2011CA2485503C Phenyl-thiophene type vitamin d receptor modulators
07/19/2011CA2483774C Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
07/19/2011CA2477232C Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
07/19/2011CA2476186C Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
07/19/2011CA2475818C Aryl ureas as kinase inhibitors
07/19/2011CA2472713C N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
07/19/2011CA2465691C 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase
07/19/2011CA2465272C Separation of regioisomers of metal phthalocyanines
07/19/2011CA2463300C Thiopene- and thiazolesulfonamides as antineoplastic agents
07/19/2011CA2459165C Dosage forms having prolonged active ingredient release
07/19/2011CA2452239C Pharmaceutical formulation having a masked taste and method for the production thereof
07/19/2011CA2448561C Aminoquinoline derivatives and their use as adenosine a3 ligands
07/19/2011CA2441996C Non-nucleoside reverse transcriptase inhibitors
07/19/2011CA2440890C Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
07/19/2011CA2432464C Excitatory amino acid receptor antagonists
07/19/2011CA2431606C Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
07/19/2011CA2420279C Selective androgen receptor modulators and methods of use thereof
07/19/2011CA2417388C Therapeutic polyanhydride compounds for drug delivery
07/19/2011CA2408920C Methods for prevention of ulcers and improving physiological performance
07/19/2011CA2401906C Kcnb: a novel potassium channel protein
07/19/2011CA2400403C 1-nitroacridine/tumor inhibitor compositions
07/19/2011CA2398747C Herbal supplement containing galanthamine for treating symptoms of estrogen-deficiency
07/19/2011CA2397354C O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
07/19/2011CA2391439C Brittle-coating, soft core dosage form
07/19/2011CA2381106C Method and composition for the control of arthropods
07/19/2011CA2380920C Use of chemical chelators as reversal agents for drug-induced neuromuscular block
07/19/2011CA2344169C Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
07/19/2011CA2341441C Methods of using and compositions comprising dopamine reuptake inhibitors
07/19/2011CA2321900C Agents with serotonin-related activity for the treatment for sleep apnea
07/19/2011CA2237590C Cyclic and heterocyclic n-substituted .alpha.-iminohydroxamic and -carboxylic acids
07/19/2011CA2188560C Compositions comprising dna damaging agents and p53
07/14/2011WO2011085361A1 Combination, kit and method of reducing intraocular pressure
07/14/2011WO2011085356A2 Povidone-iodine and sucrose wound healing dressing
07/14/2011WO2011085351A2 Method of treating kcnq related disorders
07/14/2011WO2011085347A2 Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
07/14/2011WO2011085331A1 Methods of providing weight loss therapy in patients with major depression
07/14/2011WO2011085326A1 D- amino acids for use in treating biofilms
07/14/2011WO2011085303A1 Method for hormone ablative therapy induced osteoporosis
07/14/2011WO2011085293A1 Methods and compositions for the treatment of migraine headaches
07/14/2011WO2011085291A1 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
07/14/2011WO2011085278A2 Topical scar treatment composition
07/14/2011WO2011085269A1 Raf kinase inhibitors
07/14/2011WO2011085256A2 Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
07/14/2011WO2011085216A2 Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
07/14/2011WO2011085209A2 Methods and compositions for applying moxifloxacin to the ear
07/14/2011WO2011085201A1 Fumagillol type compounds and methods of making and using same
07/14/2011WO2011085198A1 Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
07/14/2011WO2011085181A1 Taste masked topiramate composition and an orally disintegrating tablet comprising the same
07/14/2011WO2011085162A2 Topical transdermal dexmedetomidine compositions and methods of use thereof
07/14/2011WO2011085155A2 Formulations and methods for dissolving cerumen
07/14/2011WO2011085130A1 Solid state forms of fosamprenavir calcium salt and process for preparation thereof
07/14/2011WO2011085129A2 Methods and compositions of targeted drug development
07/14/2011WO2011085128A1 Hedgehog inhibitors
07/14/2011WO2011085102A1 Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
07/14/2011WO2011085067A1 Aqueous-miscible or aqueous-dispersible, voc-free biocidal compositions for the enhanced inhibition of gram-negative bacterial strains, and method of preparing the same
07/14/2011WO2011085066A2 Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
07/14/2011WO2011085039A2 Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
07/14/2011WO2011085033A2 Dp2 antagonist and uses thereof
07/14/2011WO2011085013A2 Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
07/14/2011WO2011085009A2 Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
07/14/2011WO2011085007A1 Treatment method
07/14/2011WO2011085000A2 Fatty acid derivatives and analogs of drugs
07/14/2011WO2011084985A1 Cxcr3 receptor antagonists
07/14/2011WO2011084970A1 Anti-heparin compounds
07/14/2011WO2011084968A1 A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
07/14/2011WO2011084962A1 Analogs of dehydrophenylahistins
07/14/2011WO2011084922A1 Pro-drugs of (e) -7- (3- (2-amino-1-fluoroethylidene) piperidin-1-yl) -1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
07/14/2011WO2011084898A2 Enhanced bone healing
07/14/2011WO2011084850A1 Prodrugs for the treatment of schizophrenia and bipolar disease
07/14/2011WO2011084849A1 Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
07/14/2011WO2011084848A2 Prodrugs of heteraromatic compounds
07/14/2011WO2011084781A2 Oral care compositions and methods
07/14/2011WO2011084733A1 Method of treating atrial fibrillation
07/14/2011WO2011084726A1 BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
07/14/2011WO2011084725A1 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
07/14/2011WO2011084712A1 Implantable device with intravesical tolerability and methods of treatment
07/14/2011WO2011084668A1 Nestorone®/estradiol transdermal gel
07/14/2011WO2011084653A1 Crystalline forms of the mesylate salt of a factor xa inhibitor
07/14/2011WO2011084652A2 Salts and crystalline forms of a factor xa inhibitor
07/14/2011WO2011084642A1 Compound suitable for the treatment of synucleopathies
07/14/2011WO2011084623A1 Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
07/14/2011WO2011084611A1 2-aldoximino-5-fluoropyrimidine derivatives
07/14/2011WO2011084610A1 Liposomes for preventing the spread of hiv
07/14/2011WO2011084571A2 Azide derivatives for phototherapy
07/14/2011WO2011084549A1 Homogeneous suspension of immunopotentiating compounds and uses thereof
07/14/2011WO2011084548A2 Methods and compositions for detecting recesssive familial fsgs and uses thereof
07/14/2011WO2011084519A1 Methods of synthesizing factor xa inhibitors
07/14/2011WO2011084518A2 Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same
07/14/2011WO2011084514A2 Methods and compositions for treating a malaria-related complication
07/14/2011WO2011084513A2 Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers